IngredientsOx bile β also referred to as oxgall, bovine bile, or ox bile extract β is the dried or concentrated secretion of the biliary system of the domestic cattle species Bos taurus. The term "oxgall" is used synonymously in microbiological and pharmaceutical laboratory contexts, where it is supplied as a powder derived from desiccated bovine gallbladder contents. Ox bile is a substance derived from the bile of cows, typically collected from the gallbladder and processed into supplemental form as bile salts or dried extract. In commerce and laboratory science it is most frequently encountered as "oxgall powder."
Bile acids are acidic compounds containing steroid rings; common bile acids of the body include cholic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid. Bile acids are amphipathic compounds of steroidal nature, containing at least 24 carbon atoms, which were initially thought to only ease the absorption of lipophilic compounds or assist their enterohepatic recirculation.
The only economically viable resource of bile acids is the bovine bile, which must be extracted at the time of slaughter. In slaughterhouses, the bovine gallbladder is recovered during the processing of the meat, and from a single cow around 230 mL of bile can be obtained. The commercial price of bile is in the range of $0.1β0.4 per liter. Bile acids represent roughly 0.7% (w/w) of the bile.
Today, ox bile supplements are available in various forms, including capsules, tablets, and powders, making it easier for individuals to incorporate them into their daily health regimen. An ox bile supplement is a desiccated extract of bovine bile, sold in capsule or tablet form. It belongs to the dietary supplement category and is not FDA-approved for any medical indication. Beyond dietary supplements, oxgall powders are also used as raw materials in the pharmaceutical industry to manufacture the therapeutic agents CDCA and ursodeoxycholic acid (UDCA). However, the oxgall powders used as biological agents have completely different bile acid compositions compared to those used as raw materials in the pharmaceutical industry; the latter usually undergo alkaline hydrolysis to release the precursor cholic acid for the synthesis of CDCA and UDCA.
Known primarily for its support in digestive health, particularly in individuals with bile acid deficiencies or those lacking a gallbladder, ox bile is available in supplement form, which typically contains bile acids like taurocholic and glycocholic acids. Ox bile is also frequently incorporated into multi-ingredient digestive enzyme formulas. Ox bile includes ox bile extract powder or salts that are sometimes mixed with digestive enzymes such as pancreatic protease, pancrelipase, pancreatic amylase, pancreatic lipase, betaine HCl, and certain herbs.
Forty-four different animal biles obtained from both invertebrates and vertebrates (including human bile) have been used for centuries for a host of maladies in traditional Chinese medicine (TCM), beginning with dog, ox, and common carp biles approximately in the Zhou dynasty (c. 1046β256 BCE). Bile from many different animals were recorded in TCM beginning in the Zhou dynasty from 1046β256 BCE. These bile acids were used for the treatment of gallstones, infectious skin diseases or burns, vision and eye conditions, respiratory infections, and even coma and epilepsy.
Overall, different animal biles were prescribed principally for the treatment of liver, biliary, skin (including burns), gynecological and heart diseases, as well as diseases of the eyes, ears, nose, mouth, and throat. Liquid crystals (lamellar liposomes) composed of phospholipids and cholesterol that form spontaneously in dilute non-micellar bile also have potent antioxidant properties from bound bilirubin conjugate molecules; such preparations were employed as an artificial skin and were used widely in China to dress and cover burns and battle wounds.
In traditional Chinese medicine, animal biles β though more commonly from bear, pig, or snake β were used to "clear heat," dissolve phlegm, and treat convulsions or eye diseases. While cow bile was less common in classical TCM, the general principle of bile being bitter, cooling, and detoxifying held consistent. Pig, ox, and bear bile are the more commonly used varieties in TCM today.
The use of bile as a medicine dates back to ancient Greek and Roman times, where it was associated with the theory of the four humors. "Choler" (yellow bile) and "black bile" were considered vital fluids that needed to remain in balance for health. Ox bile, in particular, was believed to influence digestion and temperament and was sometimes used in remedies for sluggishness, melancholy, and digestive troubles.
The use of ox bile in traditional medicine dates back to ancient times, with records of its application found in traditional Chinese medicine, Ayurvedic medicine, and Unani medicine. The bile of oxen was believed to possess medicinal properties, including the ability to stimulate digestion, relieve constipation, and treat various gastrointestinal disorders.
In early Western herbalism and pharmacology, ox bile was included in apothecaries' formulas to treat indigestion, constipation, and liver sluggishness. During the 19th and early 20th centuries, ox bile was widely incorporated into compound medicines, particularly in Europe and the U.S., as a treatment for chronic dyspepsia, liver congestion, and fatty liver conditions.
Bovine bile has also been central to the development of modern bile acid pharmaceuticals. When it was recognized that cortisone had a C-11 oxygen atom, it was logical to use deoxycholic acid (DCA), possessing a C-12 hydroxyl group, as a chemical precursor for the synthesis of corticosteroids. DCA was easily isolated from bovine bile or synthesized from cholic acid. At present, it is estimated that about 1,000 metric tons, or about 1,000,000 kg, of cholic acid are produced globally from bovine bile, the majority of which is used for the production of UDCA.
The primary bile acids, cholic acid and chenodeoxycholic acid, are synthesized by liver cells (hepatocytes) and concentrated in the gallbladder. Secondary bile acids, including deoxycholic and lithocholic acid, are formed by gut bacteria.
The results of analytical profiling show that nine individual bile acids are found in oxgall powders: taurocholic acid, glycocholic acid, taurodeoxycholic acid, glycodeoxycholic acid, taurochenodeoxycholic acid, glycochenodeoxycholic acid, cholic acid, chenodeoxycholic acid, and deoxycholic acid.
In mammals, bile acids are secreted as conjugated molecules with glycine or taurine, forming the so-called bile salts, with slightly different properties (pKa, solubility) in comparison to the corresponding free acids. These bile salts also lead to an increased retention in the intestine. Commercial oxgall preparations used as pharmaceutical raw materials mainly contain cholic acid (CA) and deoxycholic acid (DCA) and small amounts of chenodeoxycholic acid (CDCA), and do not contain nearly any conjugated bile acids.
Considerable variation has been found in the ratios of glycine-conjugated to taurine-conjugated bile acids, dihydroxy to trihydroxy bile acids, and free to conjugated bile acids among different commercial oxgall powders. One possible explanation for this discrepancy is that different bovine species or production technologies used by the manufacturers differ from each other. The oxgall powder from Sigma-Aldrich was closer to human bile in the ratios of glycine-conjugated bile acids to taurine-conjugated bile acids than the other tested powders. It was concluded that this powder should be used to evaluate the bile tolerance ability of probiotic bacteria as a human bile model.
Bile is a mixture of bile acids, cholesterol, phosphatidylcholine, and bilirubin. Of these, bile acids are essential constituents and play critical roles in regulation of metabolism in both humans and animal models. It contains a mix of bile acids (primarily cholic acid and deoxycholic acid), cholesterol, phospholipids, and bilirubin, and is used medicinally to support fat digestion, bile flow, and liver function.
Bile acids are potent "digestive surfactants" that promote absorption of lipids (including fat-soluble vitamins), acting as emulsifiers. Acting as natural detergents, they emulsify dietary fats into smaller droplets, increasing the surface area available for pancreatic lipases to break down fats into fatty acids and glycerol. This process is fundamental for the efficient absorption of lipids and fat-soluble vitamins in the small intestine, which is vital for maintaining normal physiological functions and energy metabolism.
As molecules with hydrophobic and hydrophilic regions, conjugated bile salts sit at the lipid/water interface and, above the right concentration, form micelles. Bile acids are essential for the formation of mixed micelles in the small intestine that facilitate solubilization, digestion, and absorption of dietary lipids and fat-soluble vitamins. The micelles present in the gallbladder also serve to solubilize cholesterol in bile, thus impairing cholesterol crystallization and gallstone formation. Bile salts induce bile flow from hepatocytes into the bile canaliculi and then gallbladder. The hepatic conversion of cholesterol to bile acids and the subsequent excretion of bile acids in the feces represent the major route for cholesterol excretion important in whole-body sterol homeostasis.
Over the last decade, it has become clear that bile acids are not simply digestive detergents and the primary route governing cholesterol catabolism. Bile acids are now recognized as hormones involved in the regulation of various metabolic processes. Bile acids are physiological detergents that absorb, distribute, metabolize, and excrete nutrients, drugs, and xenobiotics. Bile acids also are signal molecules and metabolic integrators that activate nuclear farnesoid X receptor (FXR) and membrane Takeda G protein-coupled receptor 5 (TGR5) to regulate glucose, lipid, and energy metabolism.
Bile acids activate key receptors, including Farnesoid X Receptor (FXR) and TGR5, to modulate inflammation. FXR exerts anti-inflammatory effects by suppressing NF-ΞΊB signaling and cytokine production, whereas TGR5 primarily regulates NLRP3 inflammasome activation.
FXR and TGR5 are coexpressed in enteroendocrine L cells; FXR induces TGR5 to activate cAMP and intracellular CaΒ²βΊ to secrete glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion from pancreatic Ξ² cells. In brown adipose tissue, TGR5 activation facilitates the conversion of thyroid hormone T4 to T3 by inducing type 2 deiodinase, thereby enhancing energy metabolism.
Primary bile acids synthesized in the liver are secreted into bile, stored in the gallbladder, and released to the gastrointestinal tract after food intake. Bile acids are reabsorbed mostly in the ileum and are transported back to the liver via portal blood circulation to regulate bile acid synthesis and homeostasis. Bile acids represent the primary pathway for cholesterol catabolism and account for approximately 50% of the daily turnover of cholesterol.
Bile acids are perpetually recycled via enterohepatic circulation and are biotransformed by gut microbiota, making bile acid metabolism a critical regulator of intestinal homeostasis. Once secreted into the lumen of the intestine, bile salts are modified by gut bacteria. They are partially dehydroxylated. Their glycine and taurine groups are removed to give the secondary bile acids, deoxycholic acid and lithocholic acid. Cholic acid is converted into deoxycholic acid and chenodeoxycholic acid into lithocholic acid.
Deconjugated bile acids are more hydrophobic and have greater detergent action, which increases their ability to facilitate solubilization and absorption of dietary lipids and fat-soluble vitamins and to break down bacterial membranes. Deoxycholic acid is a particularly strong antimicrobial agent, having 10 times the antimicrobial activity of cholic acid, its precursor.
However, in-vitro antimicrobial susceptibility testing, including well-diffusion and serial dilution tests to characterize the inhibitory effect of ox bile extraction on Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Propionibacterium acnes showed no antibacterial effect of ox bile against the selected gram-positive and gram-negative bacteria. Further evaluation of the antibacterial effects of different preparations of ox bile is still required.
The absorption of lipid-soluble vitamins from the diet requires the detergent actions of bile acids. Bile acids are required for proper absorption of dietary lipids, including fat-soluble vitamins. Research published in PMC found that bile acids promoted the absorption of vitamin A by promoting the absorption of fat even under low-fat diets, thereupon improving the reproduction and health of model animals.
The mechanistic evidence supporting ox bile's role in fat digestion is robust and well-established at the biochemical and physiological level. Bile acids are potent "digestive surfactants" that promote absorption of lipids (including fat-soluble vitamins), acting as emulsifiers. Bile acids have long been known to facilitate digestion and absorption of lipids in the small intestine as well as regulate cholesterol homeostasis. The mechanistic plausibility is thus strong. The clinical evidence for OTC ox bile supplementation specifically β as opposed to prescription bile acid pharmaceuticals β is more limited.
The research surrounding ox bile supplementation is moderate, showcasing its effectiveness in supporting fat digestion and overall digestive function, although the quality of evidence varies across studies.
After a cholecystectomy, bile is no longer stored or released in a controlled, concentrated manner. Instead, it trickles continuously from the liver into the small intestine in a more diluted form, regardless of whether fat is present. Without the concentrated bile release, timed with fat intake, emulsification is less efficient, leaving large globules of fat in the intestine. Since pancreatic enzymes can only digest the outside of a "glob" of fat, much of it remains in an undigested form. This can lead to fat malabsorption and symptoms such as bloating, gas, steatorrhea (fatty stools), and nutrient deficiencies (especially fat-soluble vitamins A, D, E, and K).
Formal randomized controlled trials of OTC ox bile supplements specifically for post-cholecystectomy fat malabsorption are sparse. The clinical-management literature addresses bile-acid diarrhea with prescription bile-acid sequestrants and dietary fat modification, not OTC ox bile. The mechanistic plausibility is real: biliary-related complications after cholecystectomy include fat malabsorption and bile-acid diarrhea, and post-cholecystectomy syndrome prevalence in real-world cohorts is meaningful. Functional plausibility is good; trial-level evidence for ox bile as a specific treatment is weak.
Evidence from a clinical trial using a closely related bile acid is more specific: a clinical trial using tauroursodeoxycholic acid (a bile acid) at 500 mg per day showed reduced dyspepsia in cholecystectomized patients. One area where some research exists is in individuals who have undergone cholecystectomy. A small study published in the Journal of Clinical Gastroenterology in 1992 explored the effects of bile salt supplementation in patients experiencing post-cholecystectomy symptoms. While the study had limitations, some participants reported improvement in their symptoms, suggesting a potential role for bile supplementation in this specific group.
When ox bile is studied as part of broader formulations, it is challenging to isolate the specific contribution of the ox bile component. However, the overall effectiveness of pancreatic enzyme replacement therapy, which often includes bile acids or salts, is well-documented for conditions like cystic fibrosis and pancreatic insufficiency. The most relevant guideline evidence comes from the management of short bowel syndrome, where bile acid depletion creates a similar physiological challenge to post-cholecystectomy states: ox bile supplements have been studied and found to improve fat absorption in patients with depleted bile salt pools, specifically in those who have lost more than 100 cm of ileum, without reports of significant adverse effects. The 2022 AGA guidelines note that ox bile supplements were given to improve fat absorption in bile acid-depleted states, though they acknowledge availability is limited.
The relationship between bile acids and diarrhea-predominant irritable bowel syndrome (IBS-D) is scientifically established, though it is nuanced. Bile acid excess β not deficiency β is associated with IBS-D. Compared to healthy controls, primary bile acids including cholic acid, chenodeoxycholic acid, and corresponding conjugated bile acids were significantly elevated in IBS-D patients. IBS-D patients also displayed a significant decrease of lithocholic acid. The level of total fecal bile acids was significantly elevated in the IBS-D group.
This means that ox bile supplementation is generally contraindicated in IBS-D, and the scientific evidence in this population does not support its use. Diarrhea is the most common symptom of elevated bile acids; it occurs when excess bile acids reach the colon, which is not equipped to handle the increased fat absorption, leading to loose, watery stools.
While ox bile itself is not approved for liver indications, purified bile acids derived from bovine bile β particularly ursodeoxycholic acid (UDCA) and its taurine conjugate TUDCA β have well-established clinical evidence. UDCA replaced chenodeoxycholic acid (CDCA) for gallstone dissolution throughout the world because UDCA showed efficacy similar to that of CDCA, but in contrast had virtually no hepatotoxicity.
In one clinical trial, the bile acid UDCA (13β16 mg/kg/day) prevented the worsening, improved symptoms, and prolonged survival in people with primary biliary cirrhosis. In one study, UDCA had even more striking benefits when combined with s-adenosylmethionine (SAM-e) in 19 people with this disease; the combination produced prolonged remission and reduced elevated liver enzymes, bilirubin, and cholesterol.
TUDCA has been studied in diverse clinical contexts. TUDCA is used in Europe to treat cholestatic liver disease and gallstones. It has been used in trials for liver cirrhosis, primary biliary cirrhosis, transthyretin-related amyloidosis, cholesterol gallstones, diabetes, and ALS, with a good safety profile. Diarrhea was the most common side effect noted in these studies, which utilized varied doses of TUDCA.
It is important to note that while UDCA and TUDCA are derived from bovine bile as a raw material, they are highly purified pharmaceutical agents distinct from OTC ox bile supplements, and their clinical evidence base should not be directly extrapolated to OTC ox bile products.
It has become clear that bile acids are not simply digestive detergents. Bile acids are now recognized as hormones involved in the regulation of various metabolic processes. Through activation of various signaling pathways, bile acids regulate not only their own synthesis and enterohepatic circulation, but also triglyceride, cholesterol, glucose, and energy homeostasis. These findings are based primarily on mechanistic research, animal models, and studies of pharmaceutical-grade bile acid analogs β not specifically OTC ox bile supplements in clinical trials.
The gut-to-liver axis plays a critical role in the transformation of primary bile acids to secondary bile acids, in the regulation of bile acid synthesis to maintain composition within the bile acid pool, and in the regulation of metabolic homeostasis to prevent hyperglycemia, dyslipidemia, obesity, and diabetes. Dysregulated bile acid signaling, driven by microbial dysbiosis, exacerbates inflammatory diseases like non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD). The question of whether exogenous ox bile supplementation meaningfully modulates the gut microbiome in humans remains under investigation; human clinical trial evidence specific to OTC ox bile on this endpoint is currently lacking.
UDCA can be produced by chemical transformation of cholic acid and CDCA from bovine bile. Cholic acid is the main constituent of bovine bile and is the main precursor for the synthesis of UDCA. This industrial pathway underscores the foundational pharmaceutical importance of bovine bile as a raw material.
Bile salts should be taken with meals, particularly meals that contain fat. The typical starting dose ranges from 125 mg to 500 mg of bile salts per meal, depending on the fat content of the meal and individual tolerance. Starting low and increasing gradually is advised.
In a clinical trial context for related bile acid TUDCA: Participants in a trial received 250 mg capsules, and a dose of 1 g twice daily (2 g/day) was chosen based on prior trial data in ALS across three centers in Italy. A weight-based regimen for TUDCA was used in an ulcerative colitis study administering it in 3 divided doses, corresponding to an average dose of 20β25 mg/kg/day, using 1,750 mg daily for patients under 75 kg and 2,000 mg daily for patients β₯75 kg.
A dose of 1.75 g/day corresponding to an average of 15β20 mg/kg/day has been used in human studies and has been shown to be effective with few side effects.
For OTC ox bile supplements (not pharmaceutical-grade TUDCA/UDCA), reported dosages in the supplement context are lower. An effective dose of 300 mg has been cited by evidence databases. It bears emphasis that these OTC doses are not derived from the same level of clinical trial evidence as the pharmaceutical dosages described above.
Ox bile is generally safe at recommended doses, but too much causes diarrhea and GI irritation. People with bile duct obstruction, active gallbladder disease (if they still have one), or certain liver conditions should avoid it.
Ox bile supplements are generally considered safe for most individuals; however, they may cause gastrointestinal discomfort in some users. Common side effects include nausea, diarrhea, and abdominal pain, occurring in over 5% of users. Less frequent adverse effects (1β5%) include allergic reactions, while severe allergic reactions occur in less than 1% of users. In a clinical trial of TUDCA in multiple sclerosis patients, gastrointestinal adverse events including diarrhea (11.54% vs. 0% in placebo), abdominal cramps (7.69% vs. 4.76%), and nausea/vomiting (7.69% vs. 0%) were observed in the TUDCA treatment arm.
Diarrhea is the most common symptom of elevated bile acids; it occurs when excess bile acids reach the colon. The colon is not equipped to handle the increased fat absorption, leading to loose, watery stools. Based on available animal and human data, other than the potential for diarrhea, TUDCA appears to be very well tolerated even at doses 30-fold greater than that proposed in standard clinical studies.
The supplement is contraindicated for people with a bile duct obstruction, as adding more bile to a blocked system can worsen the condition. Severe or chronic liver disease also requires caution, as compromised liver function may affect the body's ability to process supplemental bile acids. Individuals with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, should use ox bile with great care because the bile salts may exacerbate symptoms during a flare-up.
Those with inflammatory bowel diseases such as Crohn's disease or ulcerative colitis may experience worsening symptoms with ox bile supplementation. Safety has not been established for pregnant or breastfeeding women.
Chenodeoxycholic acid, present in some bile supplements, can cause too much water to be secreted into the gut, worsening diarrhea; it may also impair the gut barrier.
The potential for drug interactions exists, particularly with antacids or cholesterol-lowering medications, affecting their absorption in the gut. Cholesterol-lowering drugs (like bile acid sequestrants) have a known interaction class with bile acids. Using ox bile alongside additional digestive enzymes or fat-soluble supplements may alter absorption rates.
Notably, there are no known interactions between bile acids and antiretroviral drugs, based on evidence from a clinical protocol examining TUDCA in HIV-positive patients.
As a dietary supplement, ox bile is subject to a regulatory framework that can lead to significant variability in product standardization, where the actual concentration of bile acids may differ substantially from the label. Purity issues, including the potential for contaminants or adulteration, are also a risk in the supplement industry.
Deoxycholic acid is increased in the colonic contents of humans in response to a high-fat diet. In populations with a high incidence of colorectal cancer, fecal concentrations of bile acids are higher, particularly deoxycholic acid. The effects of ursodeoxycholic acid in modifying the risk of colorectal cancer is under study, particularly in primary sclerosing cholangitis and inflammatory bowel disease, with varying results partly related to dosage. This association is epidemiological and relates to elevated secondary bile acid levels in the colon; it does not constitute established evidence that supplemental ox bile increases cancer risk.
Health conditions that Ox bile may help support.
Bile acids refluxing into the stomach (bile reflux gastropathy) are associated with abdominal pain, fullness, dyspepsia, and nausea, documented in prospective clinical studies of post-cholecystectomy patients. Ox bile supplements taken in excess or by individuals with normal bile physiology can contribute to upper GI discomfort through the same mechanisms. Conversely, in fat malabsorption states, correcting bile deficiency reduces gas, bloating, and steatorrhea-related discomfort.
Bile acid synthesis is the primary catabolic pathway for cholesterol, accounting for approximately 50% of daily cholesterol turnover in the liver. Endogenous bile acids carry cholesterol out of the body via fecal excretion. Ox bile supplements contain pre-formed bile acids; while they do not increase hepatic synthesis, they re-enter the enterohepatic circulation and can influence luminal cholesterol solubilization and absorption.
Excess bile acids reaching the colon stimulate colonic secretion and accelerated motility, causing bile acid diarrhea (BAD). Ox bile supplementation at pharmacological doses can worsen or provoke diarrhea in susceptible individuals; conversely, in bile-deficiency states such as short bowel syndrome, ox bile has been shown to resolve steatorrhea-driven diarrhea. The relationship is therefore bidirectional and context-dependent.
Ox bile (bovine bile extract) emulsifies dietary fats, dramatically increasing the surface area available for lipase activity and enabling fat-soluble vitamin absorption. It is used therapeutically in individuals without a gallbladder or with bile acid deficiency. Digestive enzyme supplement formulations commonly include ox bile to support fat digestion.
Ox bile, derived from cattle gallbladders, contains bile acids (cholic, deoxycholic, taurocholic, glycocholic) closely mirroring human bile composition. It is used to support fat digestion and bile function post-cholecystectomy or when bile production is reduced, with strong mechanistic rationale. Traditional use in Chinese medicine for hepatobiliary function predates modern application.
Cholesterol gallstones form when the bile cholesterol-to-bile acid ratio is imbalanced. Bile acids chemically dissolve cholesterol crystals via mixed micelle formation; this principle underlies pharmaceutical ursodeoxycholic acid (UDCA) therapy for gallstone dissolution. OTC ox bile supplements lack the standardization and pharmacokinetics of prescription therapy and are not clinically validated for gallstone treatment or prevention; ox bile cannot help once stones are causing symptoms.
Bile acids are potent modulators of gut microbial ecology, exerting direct antimicrobial activity and shaping community composition through FXR signaling. Primary bile acids from ox bile supplements alter the ratio of primary to secondary bile acids in the intestinal lumen, which in turn influences the relative abundance of bile-tolerant vs. bile-sensitive bacterial taxa. The gut microbiota reciprocally biotransforms bile acids into secondary forms, creating a bidirectional axis with metabolic and immunological consequences.
There is substantial evidence that bile acid dysregulation β both excess (in IBS-D) and deficiency (in IBS-C) β contributes to IBS symptom generation. Approximately 25β33% of IBS-D patients have underlying bile acid malabsorption. Ox bile supplementation is not a recognized IBS treatment and has not been tested in IBS-specific RCTs; the relationship is mechanistic, established through studies of bile acid profiles and receptor signaling in IBS subgroups.
Bile acids are synthesized in the liver and are the primary vehicle for hepatic excretion of cholesterol, endogenous metabolites, and xenobiotics into the intestinal lumen. Adequate bile flow is therefore integral to the liver's detoxification function. Exogenous bile acids from ox bile supplements act downstream of the liver in the intestinal lumen and do not directly enhance hepatic synthesis or bile flow; they do not substitute for prescription bile acid therapy in hepatic disease.
Bile acids are now recognized as hormonal signaling molecules that regulate triglyceride, cholesterol, glucose, and energy homeostasis via FXR and TGR5 receptors. Research published in peer-reviewed journals has confirmed that bile acid pathways intersect with metabolic syndrome phenotypes. However, these metabolic effects are primarily studied with prescription bile acid analogues and sequestrants; direct metabolic evidence for OTC ox bile supplementation in humans is mechanistic rather than from RCTs.
Body systems that Ox bile may help support.
Go back